mRNA patent sequence monitoring with verifiable evidence packets
Omnis LocusTrace helps counsel, R&D, and patent operations monitor how public patent-sequence coverage changes around mRNA, IVT enzyme, and sequence-heavy programs over time.
Informational evidence infrastructure only. Not legal advice, not infringement analysis, not FTO.
- • mRNA patent monitoring
- • mRNA sequence patent search
- • IVT enzyme patent monitoring
- • patent sequence evidence packet
Start with a free 2-week trial around 1 to 3 scoped watchlists.
Human report, alert summary, and counsel packet index with hashes.
Evidence infrastructure only; no legal conclusions or infringement analysis.
Why this page exists
Sequence-heavy teams need to know what changed since the prior review, not just whether a search can find related documents.
- • Declared scope
- • Repeatable watchlists
- • Comparable packet history
Every run produces deterministic artifacts that can be forwarded and verified without trusting a dashboard session.
- • Offline verification
- • Manifest hashes
- • Structured alert summaries
LocusTrace avoids overclaiming legal outcomes and focuses on reproducible software artifacts for review workflows.
- • Not legal advice
- • Not infringement analysis
- • Not FTO
Frequently asked questions
Yes. LocusTrace is designed for sequence-heavy monitoring workflows, including mRNA, IVT enzyme, and adjacent patent-sequence watchlists.
A bounded watchlist definition using synthetic/demo-safe target sequences, IDs, motifs, or a corpus boundary, plus a clear production-key success criterion.
No. It produces informational evidence packets for counsel and R&D review. It does not provide infringement analysis, legal advice, or FTO conclusions.
A one-time search is a snapshot. LocusTrace is a repeatable monitoring workflow with declared scope and comparable outputs over time.
Bring one watchlist. Leave with evidence.
The trial is scoped around synthetic/demo-safe target sequences, IDs, motifs, or a watchlist definition. The commercial decision comes after the artifacts prove useful.